Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Capricor Therapeutics CAPR on Friday released four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD).After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline.Further, a subgroup analysis of patients with baseline Left Ventricular Ejection Fraction (LVEF) >45% showed an even greater clinical benefit, supp ...